Print

Featured Studies Results

Cancer: Ovarian

Maintenance Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer in People with a BRCA Mutation or a Biomarker Called HRD

https://www.facingourrisk.org/research-clinical-trials/study/361 /testing-olaparib-for-one-or-two-years-with-or-without-bevacizumab-to-treat-ovarian-cancer-with-a-brca-mutation-or-a-biomarker-called-hrd

Clinicaltrials.gov identifier:
NCT06580314 (https://clinicaltrials.gov/show/NCT06580314)

Treatment
Phase 3 ovarian cancer treatment study for people with BRCA mutation or HRD


A New Targeted Therapy CX‑5461 to Treat Advanced Breast, Ovarian, Pancreatic or Prostate Cancer with an ATM, BRCA1/2, CHEK2, PALB2 or Other Mutation

https://www.facingourrisk.org/research-clinical-trials/study/377 /an-new-targeted-therapy-cx5461-to-treat-advanced-breast-ovarian-pancreatic-or-prostate-cancer-with-inherited-or-tumor-mutations

Clinicaltrials.gov identifier:
NCT04890613 (https://clinicaltrials.gov/show/NCT04890613)

Treatment
Phase 1 treatment study for advanced or metastatic breast, ovarian, pancreatic or prostate cancer


Treating Advanced or Metastatic Cancers with a New PARP1 Inhibitor (GS-0201) Alone or Combined with Other Drugs

https://www.facingourrisk.org/research-clinical-trials/study/350 /treating-advanced-or-metastatic-cancers-with-the-new-parp-inhibitor-alone-or-combined-with-other-drugs

Clinicaltrials.gov identifier:
NCT06167317 (https://clinicaltrials.gov/show/NCT06167317)

Treatment
Treatment study for people with advanced or metastatic solid tumors


A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk)

https://www.facingourrisk.org/research-clinical-trials/study/101 /a-study-to-compare-two-surgical-procedures-in-women-with-brca1-mutations-to-assess-reduced-risk-of-ovarian-cancer-sorock

Clinicaltrials.gov identifier:
NCT04251052 (https://clinicaltrials.gov/show/NCT04251052)

Prevention
Ovarian cancer prevention for women with a BRCA1 mutation who still have their ovaries


Study of the Drug Olvi-Vec in Women with Ovarian Cancer

https://www.facingourrisk.org/research-clinical-trials/study/334 /study-of-the-drug-olvi-vec-in-women-with-ovarian-cancer

Clinicaltrials.gov identifier:
NCT05281471 (https://clinicaltrials.gov/show/NCT05281471)

Treatment
Treatment for women diagnosed with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer or whose cancer did not respond to prior chemotherapy


Understanding the Emotional and Social Experiences of Individuals Diagnosed with Ovarian Cancer

https://www.facingourrisk.org/research-clinical-trials/study/335 /understanding-the-emotional-and-social-experiences-of-individuals-living-with-ovarian-cancer

Surveys, Registries, Interviews
Survey for people diagnosed with ovarian cancer


Study of a New Treatment Called ONM-501 Alone and in Combination with Immunotherapy for Triple Negative Breast Cancer, Advanced Solid Tumors and Lymphomas

https://www.facingourrisk.org/research-clinical-trials/study/311 /study-of-a-new-treatment-called-onm-501-alone-and-in-combination-with-cemiplimab-in-people-with-triple-negative-breast-cancer-advanced-solid-tumors-and-lymphomas

Clinicaltrials.gov identifier:
NCT06022029 (https://clinicaltrials.gov/show/NCT06022029)

Treatment
Treatment study for people with triple negative breast cancer, advanced solid tumors or lymphomas


Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families: MicroRNA Detection Study (MiDE)

https://www.facingourrisk.org/research-clinical-trials/study/138 /validating-a-blood-test-for-early-ovarian-cancer-detection-in-high-risk-women-and-families

Prevention
Screening study for women with a BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM mutation


Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High-Risk Women

https://www.facingourrisk.org/research-clinical-trials/study/205 /risk-reducing-salpingectomy-with-delayed-oophorectomy-as-an-alternative-to-risk-reducing-salpingo-oophorectomy-in-high-risk-women

Clinicaltrials.gov identifier:
NCT05287451 (https://clinicaltrials.gov/show/NCT05287451)

Prevention
Prevention study for women at high risk for ovarian cancer


TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer

https://www.facingourrisk.org/research-clinical-trials/study/262 /tapur-study-testing-fda-approved-drugs-targeting-tumor-gene-abnormalities-in-people-with-advanced-stage-cancer

Clinicaltrials.gov identifier:
NCT02693535 (https://clinicaltrials.gov/show/NCT02693535)

Treatment
Cancer treatment study for people with advanced solid tumors


Self -Perception and Intimacy After the Cancer Experience (SPICE)

https://www.facingourrisk.org/research-clinical-trials/study/247 /self-perception-and-intimacy-after-the-cancer-experience-spice

Surveys, Registries, Interviews
Online survey for cancer survivors ages 18-39 years old about sexual health


Cancer Experience Registry

https://www.facingourrisk.org/research-clinical-trials/study/248 /cancer-experience-registry

Surveys, Registries, Interviews
Online survey for patients and caregivers focusing on multiple aspects of cancer


Treatment with an ATR Inhibitor for Advanced or Metastatic Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/157 /treatment-with-atr-inhibitor-for-advanced-or-metastatic-solid-tumors

Clinicaltrials.gov identifier:
NCT04657068 (https://clinicaltrials.gov/show/NCT04657068)

Treatment
Phase 1/2 treatment study for advanced solid tumors


Energetics and Lifestyle in Inherited Syndromes (ELLIE’s Study)

https://www.facingourrisk.org/research-clinical-trials/study/84 /ellies-project

Quality of Life
A survey for people with a hereditary cancer genetic mutation


About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.